Cytosorbents (NASDAQ:CTSO) Earns Buy Rating from D. Boral Capital

Key Points

• D. Boral Capital has reiterated a buy rating for Cytosorbents (NASDAQ:CTSO) with a target price of $10.00.
• Cytosorbents has reported earnings exceeding analyst expectations, with a quarterly EPS of ($0.05) against a consensus estimate of ($0.07).
• Institutional investors own 32.87% of Cytosorbents' stock, with Renaissance Technologies and Goldman Sachs significantly increasing their holdings recently.

Cytosorbents (NASDAQ:CTSO - Get Free Report)'s stock had its "buy" rating reaffirmed by equities researchers at D. Boral Capital in a research report issued to clients and investors on Wednesday,Benzinga reports. They presently have a $10.00 price objective on the medical research company's stock.

CTSO has been the subject of a number of other reports. Wall Street Zen started coverage on Cytosorbents in a report on Wednesday, May 21st. They set a "hold" rating for the company. HC Wainwright reiterated a "neutral" rating and set a $1.00 price objective on shares of Cytosorbents in a report on Thursday, May 15th. One investment analyst has rated the stock with a Buy rating and one has given a Hold rating to the company's stock. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $5.50.

Cytosorbents Trading Down 1.4%

Cytosorbents stock traded down $0.0131 during mid-day trading on Wednesday, hitting $0.90. The stock had a trading volume of 152,435 shares, compared to its average volume of 192,847. The stock has a 50-day simple moving average of $1.06 and a two-hundred day simple moving average of $1.03. The stock has a market capitalization of $56.48 million, a PE ratio of -5.29 and a beta of 1.19. Cytosorbents has a 12 month low of $0.7101 and a 12 month high of $1.61. The company has a current ratio of 2.34, a quick ratio of 1.96 and a debt-to-equity ratio of 1.24.

Cytosorbents (NASDAQ:CTSO - Get Free Report) last posted its quarterly earnings results on Thursday, August 7th. The medical research company reported ($0.05) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.07) by $0.02. The business had revenue of $9.62 million for the quarter, compared to analysts' expectations of $9.79 million. Cytosorbents had a negative return on equity of 111.97% and a negative net margin of 25.58%. As a group, sell-side analysts forecast that Cytosorbents will post -0.3 EPS for the current year.

Institutional Trading of Cytosorbents

Hedge funds have recently made changes to their positions in the business. Raymond James Financial Inc. acquired a new stake in shares of Cytosorbents in the fourth quarter valued at approximately $99,000. Millennium Management LLC acquired a new stake in Cytosorbents during the 4th quarter worth approximately $30,000. Skylands Capital LLC lifted its holdings in Cytosorbents by 7.9% during the 1st quarter. Skylands Capital LLC now owns 3,002,702 shares of the medical research company's stock worth $3,003,000 after purchasing an additional 221,080 shares during the last quarter. Northern Trust Corp lifted its holdings in Cytosorbents by 22.3% during the 4th quarter. Northern Trust Corp now owns 91,560 shares of the medical research company's stock worth $83,000 after purchasing an additional 16,701 shares during the last quarter. Finally, CM Management LLC lifted its holdings in Cytosorbents by 36.3% during the 1st quarter. CM Management LLC now owns 954,076 shares of the medical research company's stock worth $954,000 after purchasing an additional 254,076 shares during the last quarter. 32.87% of the stock is owned by institutional investors and hedge funds.

About Cytosorbents

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.